Form 4: Xeris Biopharma CEO Exercises Options, Sells Shares

Xeris Biopharma Holdings, Inc. CEO and Director, John Patrick Shannon Jr., reported exercising stock options and selling common stock under a Rule 10b5-1 plan.

Summary

• John Patrick Shannon Jr., CEO and Director of Xeris Biopharma Holdings, Inc., reported multiple transactions involving the company's common stock.
• On November 13, 2025, he acquired 8,970 shares of common stock by exercising stock options at an exercise price of $1.55 per share.
• On the same day, he disposed of 23,242 shares of common stock through a sale at a weighted average price of $7.4607 per share. The sales occurred within a price range of $7.260 to $7.740.
• On November 14, 2025, he acquired an additional 87,100 shares of common stock by exercising stock options, also at $1.55 per share.
• All reported transactions on November 13, 2025, were executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, John Patrick Shannon Jr.'s direct beneficial ownership of Xeris Biopharma Holdings, Inc. common stock increased to 2,730,253 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale occurred, it was part of a pre-arranged 10b5-1 plan, which mitigates negative interpretations. The exercise of options at a low strike price and subsequent sale at a much higher market price indicates a significant personal gain for the CEO, which is generally positive for executive morale and retention. The net effect on the CEO's direct holdings after all reported transactions is an increase.

Positives

• The CEO exercised a substantial number of stock options (96,070 shares in total), indicating a realization of value from previously granted equity incentives.
• The sale price of the shares ($7.4607 weighted average) is significantly higher than the option exercise price ($1.55), demonstrating a considerable personal gain for the insider.

Negatives

• The CEO sold 23,242 shares of common stock, which, while part of a 10b5-1 plan, represents a reduction in direct equity exposure from the exercised options.

Future Outlook

NA

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.260 to $7.740, inclusive.
• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
• The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan.

Industry Context

This Form 4 filing details routine insider transactions for Xeris Biopharma's CEO. Such filings are common across all industries, particularly in biopharma where executive compensation often includes significant equity components like stock options, reflecting long-term incentive structures. The use of a Rule 10b5-1 plan is a standard practice for insiders to manage their equity holdings while avoiding accusations of trading on material non-public information.

Related Party Transactions

• The transactions involve the CEO of Xeris Biopharma Holdings, Inc. exercising stock options and selling shares, which are considered related-party transactions as they involve an insider of the company.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, even under a 10b5-1 plan, could be viewed with slight caution, but the overall increase in direct beneficial ownership after the final transaction might be seen as a positive signal of continued alignment with shareholder interests.
• Employees: Executive compensation structures, including stock options, are a key part of employee incentive programs, potentially impacting morale and retention.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions by the CEO, involving the exercise of stock options and subsequent sale of a portion of the acquired shares under a pre-arranged Rule 10b5-1 plan. While the sale represents a reduction in direct holdings for a portion of the exercised options, the overall beneficial ownership increased after the final transaction. Such transactions are common and typically do not signal a fundamental shift in the company's prospects. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

Xeris Biopharma, XERS, Form 4, Insider Trading, Stock Options, CEO, Share Sale, Rule 10b5-1, Biopharma, Executive Compensation